Figure 1.

CDR profile and IgG anti-S antibodies before and after two doses of the BN162b2 vaccine [6 weeks (40-45 days) after first dose, three weeks after the second dose] in naïve individuals and in individuals that had been infected with SARS-CoV-2 before vaccination (determined by a positive SARS-CoV-2 PCR on a respiratory sample or presence of IgG anti-S and/or IgG anti-N in serum before infection) (experiment #1). The figure shows the anti-S antibody levels (A), the PCA analysis (B), heat map after hierarchical clustering of the CDR features (C) and age and gender distribution of the included individuals (D). The heat map indicates the variance (from -2 to 2) compared to the mean (0) for each peptide feature. The included vaccination/infection-induced CDR-derived peptides were those that revealed discriminative by sPLS-DA analysis. The green-labeled CDR-derived peptides were also revealed discriminative by sPLS-DA analysis in experiment #2 ( Extended Data Figure 2 ). The median [25^th-75^th percentile] anti-S antibody levels (AU/mL) were 2 [1.8-3.3], 8483 [7028-18901], 122 [86-243], and 26771 [18235-30021] pre-vaccination naïve, post-vaccination naïve, pre-vaccination infected and post-vaccination infected, respectively.